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In Brief
Methicillin-resistant Staphylococcus
aureus infection is associated with a
worse outcome. Mu¨ller et al. demonstrate
that the enzyme that confers resistance to
methicillin, PBP2A, enhances
immunopathology associated with MRSA
infection. PBP2A produces poorly cross-
linked peptidoglycan, which strongly
activates the NLRP3 inflammasome and
drives release of high amounts of IL-1b.
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Methicillin-resistant S. aureus (MRSA) is a leading
health problem. Compared to methicillin-sensitive
S. aureus, MRSA infections are associated with
greater morbidity and mortality, but the mechanisms
underlying MRSA pathogenicity are unclear. Here we
show that the protein conferring b-lactam antibiotic
resistance, penicillin-binding protein 2A (encoded by
themecA gene), directly contributes to pathogenicity
during MRSA infection. MecA induction leads to a
reduction in peptidoglycan cross-linking that allows
for enhanced degradation and detection by phago-
cytes, resulting in robust IL-1b production. Peptido-
glycan isolated from b-lactam-challenged MRSA
strongly induces the NLRP3 inflammasome in macro-
phages, but these effects are lost upon peptidoglycan
solubilization. Mutant MRSA bacteria with naturally
occurring reduced peptidoglycan cross-links induce
high IL-1b levels in vitro and cause increased pathol-
ogy in vivo.b-lactam treatment ofMRSAskin infection
exacerbates immunopathology, which is IL-1 depen-
dent. Thus, antibiotic-induced expression of mecA
duringMRSA skin infection contributes to immunopa-
thology by altering peptidoglycan structure.
INTRODUCTION
Methicillin-resistant Staphylococcus aureus (MRSA) is the most
common cause of skin and soft tissue infections in the US, but
is also a frequent cause of severe invasive diseases (Hersh
et al., 2008; Taylor, 2013). In the past decade, community-asso-
ciated MRSA (CA-MRSA) strains USA300 and USA400 have
spread endemically in the US (Kennedy et al., 2008; Oliveira
et al., 2001). Compared to infections with methicillin-sensitive
S. aureus (MSSA), MRSA infections cause greater morbidity
and mortality (Kopp et al., 2004; Antonanzas et al., 2015; Ganga
et al., 2009). The underlying reason is not entirely clear, but some
studies suggest that as-yet-unidentified pathogenic factors
contribute to the poor outcome (Watkins et al., 2012).604 Cell Host & Microbe 18, 604–612, November 11, 2015 ª2015 ElsThe genetic determinant that rendersMRSA resistant to nearly
all b-lactam antibiotics is the acquired gene mecA (Beck et al.,
1986). It codes for a penicillin-binding protein (PBP), PBP2A,
which has a lower affinity for b-lactam antibiotics compared to
the native PBPs that are the targets of this class of antibiotics
(Chambers et al., 1985). PBPs are essential for the generation
of the large cell wall polymer peptidoglycan (PGN). In addition
to extending the glycan strands, they connect individual glycan
strands in a process termed transpeptidation (Sauvage et al.,
2008). The domain of PBPs catalyzing this transpeptidation re-
action is inhibited by b-lactam antibiotics. Hence, in the pres-
ence of b-lactam antibiotics, endogenous PBPs are inactivated
(Tomasz, 1979). Not constitutively expressed, mecA is strongly
upregulated upon challenge of MRSA with b-lactam antibiotics,
and all transpeptidation events are then carried out by PBP2A
(de Jonge and Tomasz, 1993). Therefore, MRSA survives at con-
centrations of b-lactam antibiotics usually administered to
patients.
Even though MRSA survives in the presence of b-lactam anti-
biotics, its PGN is structurally different from PGNmade by native
PBPs. b-lactam challenge of MRSA leads to a reduction of mur-
opeptide cross-linking (de Jonge and Tomasz, 1993). PBP2A is
able to connect muropeptides to form dimers but is unable to
accept dimers as substrates for further cross-linking (de Jonge
et al., 1992). Hence, if PBP2A is the only functional PBP enzyme
left due to antibiotic inactivation of native PBPs, the degree of
PGN cross-linking is low.
S. aureus modifies its PGN in a way that makes it resistant to
intracellular degradation by immune cells (Bera et al., 2005). We
have previously shown that PGN from a S. aureus mutant with
reduced resistance to intracellular PGN degradation stimulates
greater production of inflammatory cytokines by macrophages
than native PGN (Wolf et al., 2011; Shimada et al., 2010). This
increased inflammatory response is especially evident in the
activation of the NLRP3 inflammasome and increased produc-
tion of IL-1b. Degradation-sensitive bacteria are more efficiently
killed by host immune cells in vivo but cause increased IL-
1b-induced immunopathology in a mouse skin infection model
(Shimada et al., 2010).
Because challenge of MRSA with b-lactam antibiotics causes
reduced muropeptide cross-linking of PGN in the cell wall, we
hypothesized that these bacteria might induce an altered inflam-
matory response. Such an altered innate inflammatory responseevier Inc.
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Figure 1. PGN Made by PBP2A Has
Reduced Muropeptide Cross-Links and In-
duces Robust IL-1b Secretion by Macro-
phages
(A and B) PGNwas purified fromMRSA and grown
overnight with or without cefoxitin. HPLC profiles
of muropeptides from PGN derived from untreated
(A) or cefoxitin-treated (B) MRSA are shown.
Fragments with reduced cross-links have a short
elution time.
(C and D) PGN from untreated or cefoxitin-treated
MRSA was used to stimulate murine BMDM (C),
or human monocyte-derived macrophages (D)
(80 mg/ml PGN) (data are representative of three
experiments for C).
(E) PGN from MRSA treated with cefoxitin (Cef),
ampicillin (Amp), or nafcillin (Naf) was used to
stimulate murine BMDM (data are representative
of four experiments).
(F)mecAmRNA from MRSA grown for 4 hr with or
without cefoxitin was measured by qRT-PCR and
standardized against expression of 16S rRNA
(data are representative of two experiments).
(G) IL-1b release by murine BMDM incubated with
live MRSA pretreated with cefoxitin for 4 hr (data
are representative of three experiments).
(H) IL-1b stimulatory activity of clinical MRSA
strains grown in the presence or absence of
cefoxitin (data are representative of two experi-
ments).
For (C)–(E), (G), and (H) data are presented as
mean ± SD. See also Figure S1.could lead to increased immunopathology and might contribute
to the noted difference in morbidity between MRSA and MSSA
infections.
RESULTS
PGN Made by PBP2A Is Poorly Cross-Linked and
Strongly Induces IL-1b
To investigate whether antibiotic resistance is positively corre-
lated with inflammatory responses, we first examined the effects
of b-lactam antibiotics on PGN structure. Consistent with pub-
lished findings (de Jonge and Tomasz, 1993), HPLC analysis
showed that PGN from MRSA (USA300 JE2 strain) is highly
cross-linkedwhen grown in the absence of antibiotics (Figure 1A)
but is poorly cross-linked when the bacteria are challenged with
the b-lactam antibiotic cefoxitin, to which the bacteria are fully
resistant (Figure 1B).
To testwhetherb-lactam treatment ofMRSA leads to increased
cytokine production due to structural changes in PGN,wepurifiedCell Host & Microbe 18, 604–612, NPGN from cefoxitin-challenged and un-
challenged MRSA and used it to stimulate
primary mouse bone marrow-derived
macrophages (BMDM). PGN from MRSA
treated with b-lactam antibiotics induced
higher IL-1b, IL-6, TNF-a, and IL-1a levels
compared to PGN from untreated MRSA
(Figures 1C and S1A-S1C), though among
these cytokines, the b-lactam effect wasmost pronounced on IL-1b. Human monocyte-derived macro-
phages showed a similar increase in IL-1b secretion after stimula-
tion with PGN from bacteria exposed to cefoxitin (Figure 1D). This
effectwas not specific to cefoxitin butwas also seenwhenBMDM
were stimulated with PGN from ampicillin-challenged or nafcillin-
challenged MRSA (Figure 1E). MRSA grown in the presence of
different concentrations of cefoxitin strongly upregulated mecA
(Figure 1F), and these whole bacteria induced higher IL-1b secre-
tion frommacrophagescompared tountreatedMRSA (Figure1G).
Similar to the data presented for cefoxitin, MRSA challenged with
ampicillin produced PGN with reduced cross-links and induced
increased cytokine levels as mecA is induced (Figures
S1D–S1F). In the presence of b-lactams, PBP2A expression is
induced, and as the dose of antibiotic increases, which progres-
sively inhibits native PBPs, transpeptidation reactions are per-
formed more prominently by PBP2A. Increasing use of PBP2A
would lead to a decrease in PGN cross-linking up to the point
when transpeptidation is performed exclusively by PBP2A. In
addition to the USA 300 JE2 strain, other MRSA clinical strainsovember 11, 2015 ª2015 Elsevier Inc. 605
triggered increased IL-1b release after challenge with cefoxitin
(Figure 1H). Besides MRSA, the human opportunistic pathogen
S. epidermidis also synthesizes PBP2A to resist killing by b-lac-
tamantibiotics. AmecA-positiveS. epidermidis strain or PGN iso-
lated from it also induced higher IL-1b levels after cefoxitin treat-
ment (Figures S1G–S1I). Taken together, mecA expression in
MRSA leads to structural changes in PGN composition, which
correlates with increased IL-1b secretion by macrophages.
PGN Made by PBP2A in the Presence of b-Lactam
Antibiotics Is a Potent Activator of the Inflammasome
PGN-induced secretion of IL-1b by macrophages requires stim-
ulation of IL-1b mRNA production, synthesis of pro-IL-1b pro-
tein, and activation of the NLRP3 inflammasome to process
and release mature IL-1b (Agostini et al., 2004; Garlanda
et al., 2013). We stimulated mouse BMDM with PGN from bac-
teria treated or untreated with cefoxitin and observed that in-
duction of IL-1b mRNA was not different (Figure 2A). This sug-
gests that PGN made by PBP2A (from cefoxitin-challenged
MRSA) is a more potent activator of the inflammasome. To
isolate inflammasome activation from IL-1b mRNA induction,
we primed macrophages with lipopolysaccharide (LPS) to
strongly induce IL-1b mRNA and then measured the ability of
PGN from antibiotic-treated MRSA to trigger release of IL-1b
in a short time period (6 hr). PGN from untreated MRSA hardly
induced IL-1b secretion in this time frame, whereas PGN from
antibiotic-treated MRSA strongly induced IL-1b release (Fig-
ure 2B) and caspase-1 activation (Figure 2C). In addition, we
confirmed release of cleaved IL-1b in the culture supernatants
by immunoblotting (Figure S2A). In accordance with IL-1b
mRNA levels, protein levels of pro-IL-1b were not different in
cell lysates from LPS-primed PGN-stimulated BMDM (Fig-
ure S2B). We similarly observed that antibiotic-treated, heat-
killed (HK) MRSA activated caspase-1 cleavage more effec-
tively than untreated HK MRSA in LPS-primed macrophages
(Figure S2C). The increase in IL-1b secretion in response to
PBP2A-made PGN is completely dependent on the NLRP3
inflammasome and caspase-1 (Figure 2D). Activation of the in-
flammasome by strong stimuli such as ATP or nigericin is
commonly accompanied by pyroptosis. However, even though
we observed higher IL-1b levels in response to PGN from cefox-
itin-challenged MRSA compared to unchallenged MRSA,
we did not observe increased cell death (Figure S2D). This is
in line with our previous study showing that PGN from
S. aureus does not induce pyroptosis in BMDM (Shimada
et al., 2010). Together, the data suggest that the increased
IL-1b secretion in response to PBP2A-made PGN and antibi-
otic-treated MRSA is due to stronger activation of the
inflammasome.
To determine whether inflammasome activation is induced by
PGN and not by some unknown co-purifying factor that is
produced by antibiotic-exposed MRSA, we digested MRSA
PGN with lysostaphin, an enzyme that specifically cleaves the
cross-linking pentaglycine bridges in PGN from Staphylococci.
The enzyme completely solubilized the particulate material and
abrogated its ability to stimulate IL-1b secretion by macro-
phages (Figure 2E), suggesting that the IL-1b production is not
due to a factor other than PGN. We have previously observed
that inflammasome activation in response to PGN requires its606 Cell Host & Microbe 18, 604–612, November 11, 2015 ª2015 Elsdegradation within phagosomes (Shimada et al., 2010). Inhibi-
tion of phagocytosis with cytochalasin D (Figure 2F), inhibition
of acidification of the endolysosomal/phagolysosomal compart-
mentwith bafilomycin A1 (Figure 2G), and inhibition of proteolytic
enzymes with the protease inhibitor E64d (Figure 2H) markedly
decreased IL-1b secretion upon macrophage stimulation with
PBP2A-made PGN. The PGN made by PBP2A and the PGN
made by native PBPs were internalized equivalently by macro-
phages, ruling out differences in contact and phagocytosis effi-
ciency as factors in the differential IL-1b response (Figures S2E
and S2F). We hypothesized that the poor cross-linking of PGN
made by cefoxitin-treated bacteria makes PGN more suscepti-
ble to degradation by macrophages. To test this, we purified ly-
sosomes from BMDM and incubated the lysosomal extract with
PGN from either untreated or b-lactam-treated MRSA. As pre-
dicted, PGN from cefoxitin-challenged MRSA was more effi-
ciently degraded by lysosomal enzymes compared to PGN
from unchallenged MRSA (Figure 2I). In line with this finding,
MRSA treated with cefoxitin or ampicillin showed reduced intra-
cellular survival in macrophages (Figures 2J and S2G). This was
not due to a general growth disadvantage of antibiotic-chal-
lenged MRSA since they regrew normally in antibiotic-free me-
dium after antibiotic challenge (Figure 2K). Together the data
suggest that the structural change in PGN caused by PBP2A in
the presence of b-lactam antibiotics causes it to become a
more potent activator of the inflammasome.
Reduced PGN Cross-Linking Is Sufficient to Enhance
PGN-Induced IL-1b Production
To test the hypothesis that reducing the degree of cross-linking
in PGN leads to greater inflammatory responses, we digested
PGN from unchallengedMRSAwith various concentrations of ly-
sostaphin. At low lysostaphin concentrations (at which PGN
cross-links are not yet fully degraded and the material is still par-
ticulate), the PGN made by endogenous PBPs induced IL-1b
release to the same extent as PGN made after PBP2A induction
with antibiotics (Figure 3A). As the lysostaphin concentrationwas
increased and the PGN was solubilized, it lost its ability to stim-
ulate IL-1b production. Thus, reducing the cross-linking of par-
ticulate PGN is sufficient to cause it to stimulate more IL-1b
production.
MSSA exposed to sub-lethal doses of b-lactam antibiotics
also leads to poorly cross-linked PGN, presumably by reducing
the efficiency of antibiotic-sensitive PBPs (de Jonge et al., 1992).
If so, this too should increase inflammasome activation. Indeed,
when a mecA-transposon (Tn) mutant of the MRSA JE2 strain
was challenged with sub-lethal doses of cefoxitin (Figure 3B)
or ampicillin (Figure S3A) and then used to infect macrophages,
the antibiotic treatments led to increased IL-1b secretion. PGN
purified from the low-dose cefoxitin-treated mecA-Tn mutant
strongly induced IL-1b secretion from macrophages, while
PGN from the untreated mecA-Tn mutant did not (Figure 3C).
We also used a genetic approach to specifically manipulate
PGN cross-linking. It was recently reported that MRSA mutants
for PBP4 and the protease ClpP show an abnormal low or high
degree of PGN cross-linking, respectively (Bæk et al., 2014;
Memmi et al., 2008). When isogenic strains of these bacteria
(Figure 3D), or PGN isolated from them (Figure 3E), were used
to infect macrophages, the pbpD-Tn mutant proved to beevier Inc.
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Figure 2. PGN Made by PBP2A Requires Intracellular Degradation to Activate the Inflammasome
PGN from MRSA grown overnight in the absence or presence of cefoxitin was used in macrophage stimulation assays.
(A) IL-1b mRNA expression (relative to b-actin mRNA) by BMDM challenged with PGN (40 mg/ml) for 6 hr (n = 3).
(B) IL-1b release by LPS-primed BMDM incubated with PGN (40 mg/ml) (data are representative of three experiments).
(C) Detection of cleaved caspase-1 in supernatants of LPS-primed PGN-stimulated BMDM (data are representative of four experiments).
(D) IL-1b release by WT, Nlrp3/, and Casp1/ BMDMs after overnight stimulation with PGN (80 mg/ml) (data are representative of four experiments).
(legend continued on next page)
Cell Host & Microbe 18, 604–612, November 11, 2015 ª2015 Elsevier Inc. 607
more potent and the clpP-Tn mutant proved to be less active in
inducing IL-1b. This is consistent with our hypothesis that the de-
gree of PGN cross-linking directly determines the amount of IL-
1b that is secreted and that this correlates with the degradability
of PGN by lysosomal enzymes (Figures S3B and S3C). In vivo,
mice infected with pbpD-Tn mutant had bigger skin lesions
compared to WT MRSA (Figures 3F and 3G), which was not
due to a higher bacterial burden of the pbpD-Tn mutant
compared to WT MRSA (Figure S3D). Overall, these data show
that reducing PGN cross-linking is sufficient to cause enhanced
inflammatory responses in vitro and in vivo.
b-Lactam-Challenged MRSA Causes More Severe IL-1-
Dependent Skin Immunopathology In Vivo
To determine if b-lactam treatment of MRSA in vivo induces
greater skin immunopathology, we next injected WT mice sub-
cutaneously (s.c.) with PGN from cefoxitin-challenged and un-
challenged MRSA. Higher IL-1b levels and neutrophil recruit-
ment were detected in the skin of mice that had received
PGN from antibiotic-treated MRSA (Figures 4A and S4A).
Next, we injected HK MRSA, treated or untreated with cefox-
itin, into the skin of mice. HK bacteria were used to avoid ef-
fects on skin pathology that might arise from differential
expression of toxins in response to antibiotic challenge (Ohlsen
et al., 1998). HK antibiotic-challenged MRSA induced signifi-
cantly higher levels of IL-1b, abscess weight, and abscess vol-
ume compared to unchallenged HK MRSA (Figures 4B, 4C,
and S4B). Finally, we infected mice s.c. with live MRSA and
treated the mice starting 1 day after and twice daily with either
PBS or nafcillin. Antibiotic treatment of the MRSA infection
significantly increased lesion size in comparison to no treat-
ment (Figures 4D and S4C). In support of our hypothesis that
increased inflammation rather than bacterial virulence contrib-
utes to immunopathology, we found reduced numbers of bac-
teria in lesions from antibiotic-treated animals (Figure 4E).
Furthermore, we found increased numbers of neutrophils in le-
sions from MRSA-infected mice treated with nafcillin
compared to PBS-treated mice (Figure 4F). This is consistent
with the interpretation that although the bacteria are resistant
to the antibiotic, they are killed more effectively by phagocytes
in the presence of the antibiotic. The immunopathology
induced by b-lactams appeared to be dependent on IL-1
signaling, as the differences in abscess weight and volume
induced by antibiotic-treated HK MRSA compared to un-
treated HK MRSA were abrogated in IL-1R1/ mice (Figures
4G and 4H). Overall, these data suggest that the well-studied
antibiotic resistance factor PBP2A is also an as-yet-unrecog-
nized pathogenic factor during MRSA infections. b-lactam an-
tibiotics therefore not only are ineffective against MRSA infec-
tions, but actually contribute to immunopathology by inducing
mecA.(E) Effect of lysostaphin-degraded PGN (40 mg/ml) from cefoxitin-challenged or un
experiments).
(F–H) IL-1b release by BMDM treated with cytochalasin D (F), bafilomycin A1 (G), o
experiments).
(I) Degradation of PGN by purified lysosomal extract after 24 hr (n = 4).
(J) Effect of cefoxitin on MRSA survival within BMDMs. The assay was repeated
(K) Growth curve of MRSA initially cultured with or without cefoxitin and subsequ
For (A) and (I) data are presented as mean ± SE. For (B) and (D)–(H) data are pre
608 Cell Host & Microbe 18, 604–612, November 11, 2015 ª2015 ElsDISCUSSION
Many studies have compared the outcome of MSSA and MRSA
infections. A meta-analysis of these studies determined that
MRSA infections are associated with worse outcomes
compared to MSSA even after adjusting for comorbidities and
severity of initial diseases (Cosgrove et al., 2003). Several under-
lying reasons are offered for the finding, including reduced effi-
cacy of many anti-MRSA antibiotics (Deresinski, 2007), delay in
appropriate treatment because of failure to recognize MRSA
infection (Kim et al., 2004), and the possibility that MRSA is
more pathogenic compared to MSSA. Though the association
of MRSA with increased pathogenicity has been suggested by
several clinical studies, pertinent pathogenic factors have not
been identified (Barrios Lo´pez et al., 2013; Watkins et al.,
2012). In this study we demonstrated that PBP2A, the factor
that makes MRSA resistant to b-lactam treatment, contributes
to the pathogenicity of MRSA infection by changing PGN struc-
ture and augmenting immunopathology, although this effect is
not observed until mecA is induced by b-lactam antibiotics.
This finding provides some insight on the difference in
outcome between MRSA and MSSA infections. Based on re-
ports, between 30% and 80% of individuals infected with
MRSA were inappropriately treated, often with b-lactam antibi-
otics (Paul et al., 2010; Kim et al., 2004; Rodrı´guez-Ban˜o et al.,
2009). Studies confirmed that initial inappropriate antibiotic
treatment is an independent predictive factor for mortality during
MRSA bacteremia (Gasch et al., 2013). Although lack of aware-
ness of MRSA likely contributed to some of these cases, tech-
nical limitations in rapid diagnosis of MRSA and the pressure
to not over-prescribe vancomycin, the gold standard for MRSA
treatment, will likely lead to more prescription of b-lactam antibi-
otics (e.g., ceftriaxone). Our study, upon additional clinical
corroboration, may therefore suggest caution in the use of b-lac-
tams, whichmay lead to a worse outcome compared to inaction.
Aside from MRSA, treatment of MSSA with sub-lethal doses of
b-lactam antibiotics could also lead to a reduction of PGN
cross-links, and this would be predicted to induce increased
inflammation. However, the use of low doses of b-lactam antibi-
otics is likely less clinically relevant.
Our data suggest that reduction ofmuropeptidecross-linking in-
creases MRSA susceptibility to intracellular degradation followed
by killing by macrophages. We have previously shown that
S. aureus PGN structure and PGN degradability by immune cells
impact cytokine production by macrophages and dendritic cells
and that IL-1b responses are particularly strongly affected (Shi-
mada et al., 2010; Wolf et al., 2011). IL-1b is thought to be
a critical cytokine for effective control of S. aureus skin infections
(Miller et al., 2006), being particularly important for recruitment
of neutrophils (Cho et al., 2012). However, increased neutrophil
recruitmentandactivationcanpotentially cause immunopathologychallengedMRSA on IL-1b release by BMDMs (data are representative of three
r E64d (H) and stimulated with PGN (40 mg/ml) (data are representative of three
with ampicillin-treated MRSA (Figure S2G).
ently grown in antibiotic-free media.
sented as mean ± SD. See also Figure S2.
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Figure 3. Alteration in PGN Cross-Links Affects IL-1b Release from Macrophages
(A) PGN derived from untreated or cefoxitin-treated MRSA was digested with lysostaphin for 2 hr and then used to stimulate LPS-primed BMDMs.
(B and C) Effect of low cefoxitin concentrations on MSSA-induced (B) or PGN-induced (C) IL-1b release by BMDMs.
(D and E) IL-1b release by BMDM stimulated with live JE2 WT, pbpD-Tn mutant (reduced PGN cross-links), or clpP-Tn mutant (excessive PGN cross-links)
bacteria (D) or PGN (80 mg/ml) isolated from these bacterial strains (E).
(F andG)WTmicewere infected on the right flankwithWT JE2 (107 CFUs) and on the left flankwith JE2pbpD-Tnmutant (107 CFUs). Skin lesionsmeasuredon day 1
(F) and on consecutive days (G). Also shown are two images of the lesions (n = 2 with 19 total animals). Wilcoxon rank-sum test was used; *p < 0.05, **p < 0.01.
For (A)–(E) data are representative of 2–5 experiments and presented as mean ± SD. For (G) data are presented as mean ± SE. See also Figure S3.
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Figure 4. MRSA and PGN Induce Greater IL-1b Levels and Immunopathology In Vivo after b-Lactam Treatment
(A) Skin IL-1b levels in WT mice injected s.c. with PGN derived from untreated or cefoxitin-treated MRSA.
(B and C) Skin IL-1b levels (B) and abscess weight (C) on day 3 from WT mice injected s.c. with HK, untreated, or cefoxitin-pretreated MRSA (5 3 108 CFUs).
(D–F) WT mice infected s.c. with MRSA (3 3 107 CFUs) were treated starting on day 1 and twice a day s.c. with PBS or 5 mg/ml nafcillin at the site of infection.
Average lesion sizes (D), bacterial burden (E), and neutrophils (F) at the site of infection on day 3 (n = 2).
(G and H) HK, untreated, or cefoxitin-pretreatedMRSA (108 CFUs) were injected s.c. intoWT or IL-1R1/mice. Abscess weight (G) and abscess volume (H) after
3 days. Mann-Whitney U test was used. *p < 0.05.
For (D) data are presented as mean ± SE. See also Figure S4.
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as observed in our study, so the process must be balanced care-
fully (Fournier and Parkos, 2012; Yang et al., 2013).
One recent publication reported that nafcillin treatment in vivo
‘‘sensitizes’’ MRSA to killing by the innate immune system,
although the mechanism of this response was not clear (Sakou-
las et al., 2014). This is in line with our in vitro data showing
increased susceptibility of b-lactam-challenged MRSA to
macrophage-mediated killing, as well as reduced CFU numbers
in vivo upon nafcillin treatment. Interestingly a murine and two
human studies recently showed that the combination of b-lac-
tam antibiotics with vancomycin or daptomycin is more effective
in MRSA infections compared to vancomycin or daptomycin
treatment alone, leading to enhanced bacterial clearance (Dil-
worth et al., 2014; Yang et al., 2010; Dhand et al., 2011). Our
work provides a possible mechanistic explanation for the
improved bacterial clearance observed in these studies.
Since many antibiotics target PGN assembly by S. aureus and
other bacteria, it is important to understand how the develop-
ment of bacterial resistance affects the overall immune response
to these pathogens. Here we provide evidence that the resis-
tance machinery of MRSA, through mecA induction, results in
increased inflammation in response to the pathogen.
EXPERIMENTAL PROCEDURES
Animals
C57BL/6 mice were purchased from Charles River and were between 7 and
12 weeks of age during experiments. IL-1R1/ mice (The Jackson Labora-
tory) were bred at Cedars-Sinai Medical Center.
Bacterial Strains
Unless otherwise indicated, the MRSA USA300 strain JE2 was used for all ex-
periments. JE2 transposon insertion mutants of mecA, pbpD, and clpP from
The Nebraska Transposon Mutant Library were obtained from the NARSA
repository. The USA400 strain MW2 and two clinical strains isolated at Ce-
dars-Sinai Medical Center (MRSA strain CST10 and a mecA-positive
S. epidermidis strain; Figure S1G) were also studied.
Cell Culture
BMDMs were generated as previously described (Wolf et al., 2011). BMDMs
were cultured in 1640 RPMI without glucose (Life Technologies), 10% FCS
(Sigma), 1% penicillin/streptomycin, 1% L-glutamine, and 5 mM glucose
(United States Biological). Nlrp3/ (Kuida et al., 1995) and Casp1/ (Maria-
thasan et al., 2006) BMDMs were kindly provided by Dr. Moshe Arditi.
Macrophage Killing Assay
The assay was performed as previously described (Mu¨ller et al., 2014). In brief,
macrophages plated in 24-well plates were infected with MRSA (MOI 10)
grown in antibiotics overnight. After 45 min, antibiotic-free cell culture medium
was replaced bymedium containing 100 mg/ml gentamicin to kill the remaining
extracellular bacteria. Macrophages were lysed at the indicated time points,
and bacterial CFUs were determined.
Skin Infection
Mice were shaved the day before injection. When PGN was injected, 200 mg
PGN was administered in a total volume of 100 ml PBS. 108 or 5 3 108 HK
MRSA were injected in 100 ml PBS. For injection of live MRSA, bacteria were
prepared as described in the Supplemental Experimental Procedures, and
3 3 107 CFUs were injected s.c. in 100 ml PBS. If not indicated otherwise,
skin lesions were excised, homogenized, and plated to determine CFUs on
day 3. Afterward, the homogenate was centrifuged for 5 min and the superna-
tant was used for cytokinemeasurement. The remaining pellet was further pro-
cessed in some experiments for FACS analysis.Cell Host &Ethics Statement
This study was performed under strict accordance with the recommendations
in the Guide for the Care and Use of Laboratory Animals. The protocol was
approved by the institutional animal care and use committee of the Cedars-
Sinai Medical Center (IACUC 3402). Experimentations using human blood
were approved by the Cedars-Sinai Medical Center Institutional Review Board
(Pro00009792). Human blood was obtained from adult volunteers, and
informed written consent was obtained prior to the blood draw.
Statistical Analysis
When a representative experiment is shown, data are presented asmean ± SD
of replicates. Otherwise, data are presented as mean ± SE or individual data
points are shown in graphs. Statistical analysis was performed using
non-parametric Mann-Whitney U test or Wilcoxon signed-rank test. p values
less than 0.5 were considered significant.
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and four figures and can be found with this article online at http://dx.doi.org/
10.1016/j.chom.2015.10.011.
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